Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
Status:
Completed
Trial end date:
2007-11-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the objective tumor response rate (based on the
RECIST criteria) to SNS-595 as a second-line therapy in patients with advanced NSCLC.